Talaris Therapeutics (TALS) executive Fenton received 150,000 Stock Option (Right to Buy)

Insider transactions reported

Mary Kay Fenton (executive at Talaris Therapeutics Inc., TALS) reported that they received 150,000 Stock Option (Right to Buy) on Feb 1, 2023.

Reporting person

Fenton Mary Kay

Options and other derivatives

Holdings before and after

• Stock Option (Right to Buy): 0 to 150,000 direct
• Stock Appreciation Right: 0 to 150,000 direct

Footnotes from the filing

1. 1. The shares underlying this option shall vest as follows: one-third on August 1, 2023 and the remaining two-thirds on August 1, 2024.
2. 2. Each Time Vested Stock Appreciation Right ( TV SAR ) represents the right to receive either, (i) the largest whole number of shares of stock with a value closest to, but not in excess of, the product of the increase in fair market value of one share of common stock from the date of grant of the TV SAR to the date of exercise of the TV SAR, multiplied by the number of shares of common stock underlying the TV SAR that is being exercised, or (ii) the Company may elect to make cash payment measured by the increase in the fair market value of one share of common stock from the date of grant of the TV SAR to the date of exercise of the TV SAR. One-third of the TV SAR awards will vest on August 1, 2023 and the remaining two-thirds will vest on August 1, 2024. The TV SAR awards expire on February 1, 2033 and have an exercise price of $1.73 per share, the closing price of the common stock on the grant date.

Transaction codes in this filing

Grant or award:

Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.

FAQ